Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains - Publication - MOST Wiedzy

Search

Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains

Abstract

Urinary tract infections (UTIs) are the most widespread and annoying infections affecting millions of people every year annually. The biggest problem of urinary diseases are recurrences, the increasing resistance of uropathogens to commonly used antibiotics, as well as the high health care costs of afflicted persons. Uropathogenic Escherichia coli strains (UPECs) are the most dominant etiologic agent of community-acquired infections of this type. During UTI pathogenesis, UPECs utilize various virulence factors, especially mono- and polyadhesive appendages of the chaperone-usher secretion pathway (CUP) required for adhesion, invasion and biofilm formation. The commonly used antibiotics for UTI treatment are usually effective, but their long-term utility may affect the gut microbiota of treated individuals and cause a selection of drug resistant uropathogenic variants. Due to the increasing resistance of UPEC strains to antibiotics via the evolution of specific defense mechanisms there is a need to develop alternative methods and therapeutic strategies to fight UTIs (vaccines, receptor analogues, pilicides and curlicides, bacterial interference or phagotherapy). Such therapeutic approaches usually target the processes enabling uropathogens to survive within urinary tract and cause recurrent infections.

Citations

  • 1

    CrossRef

  • 2

    Web of Science

  • 2

    Scopus

Details

Category:
Articles
Type:
artykuł w czasopiśmie wyróżnionym w JCR
Published in:
Acta Biochimica Polonica no. 66, pages 129 - 138,
ISSN: 0001-527X
Language:
English
Publication year:
2019
Bibliographic description:
Zalewska-Piątek B., Piątek R.: Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains// Acta Biochimica Polonica. -Vol. 66, iss. 2 (2019), s.129-138
DOI:
Digital Object Identifier (open in new tab) 10.18388/abp.2018_2787
Bibliography: test
  1. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treat- ment of human in fections. Bacteriophage 1: 66-85. https://doi. org/10.4161/bact.1.2.15845 open in new tab
  2. Åberg V, Almqvist F (2007) Pilicides-small molecules targeting bacterial virulence. Org Biomogl Chem 5: 1827-1834. https://doi.org/10.1039/ b702397a open in new tab
  3. Aberg V, Fällman E, Axner O, Uhlin BE, Hultgren SJ, Almqvist F (2007) Pilicides regulate pili expression in E. coli without affecting the functional properties of the pilus rod. Mol Biosyst 3: 214-218. https://doi.org/10.1039/b613441f open in new tab
  4. Aberg V, Hedenström M, Pinkner JS, Hultgren SJ, Almqvist F (2005) C-Terminal properties are important for ring-fused 2-pyridones that interfere with the chaperone function in uropathogenic E. coli. Org Biomol Chem 3: 3886-3892. https://doi.org/10.1039/b509376g open in new tab
  5. Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL (2009) Mu- cosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog 5: e1000586. https://doi. org/10.1371/journal.ppat.1000586 open in new tab
  6. Arshba C, Bagdoeva K (1965) Application of phagetherapy against colibacterial infections of urinary tract. Clin Exp Urol 3: 7-13
  7. Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, Bouzari S (2013) Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infec- tion in mice. Vaccine 31: 1210-1216. https://doi.org/10.1016/j.vac- cine.2012.12.059 open in new tab
  8. Barnhart MM, Chapman MR (2006) Curli biogenesis and function. Annu Rev Microbiol 60: 131-147. https://doi.org/10.1146/annurev. micro.60.080805.142106 open in new tab
  9. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G (2013) Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol 190: 1981-1989. https://doi.org/10.1016/j. juro.2013.04.142 open in new tab
  10. Bian Z, Normark S (1997) Nucleator function of CsgB for the as- sembly of adhesive surface organelles in Escherichia coli. EMBO J 16: 5827-5836. https://doi.org/10.1093/emboj/16.19.5827 open in new tab
  11. Bonkat, G, Pickard R, Bartoletti R, Cai T, Bruyère F, Geerlings SE, Wagenlehner F, Wullt B. Guidelines Associates: T. Cai , B. Köves, A. Pilatz, B. Pradere, R. Veeratterapillay (2018) European Asso- ciation of Urology (EAU) Guidelines on Urological Infections pp. 247-269. ISBN 978-90-79754-91-5. https://www.uroweb.org/guide- lines
  12. Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhr- er M, Hung CS, Pinkner J, Slattegard R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H (2005) Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 55: 441-455. https://doi.org/10.1111/j.1365- 2958.2004.04415.x open in new tab
  13. Brumbaugh AR, Mobley HL (2012) Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Rev Vac- cines 11: 663-676. https://doi.org/10.1586/erv.12.36 open in new tab
  14. Brumbaugh AR, Smith SN, Mobley HL (2013) Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect Immun 81: 3309-3316. https://doi.org/10.1128/IAI.00470-13 open in new tab
  15. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP (2016) Burden of six healthcare-associated infections on European popula- tion health: estimating incidence-based disability-adjusted life years through a population prevalence-based modeling study. PLoS Med 13: e1002150. https://doi.org/10.1371/journal.pmed.1002150 open in new tab
  16. Cecioni S, Imberty A, Vidal S (2015) Glycomimetics versus multivalent glycoconjugates for the design of high affinity lectin ligands. Chem Rev 115: 525-561. https://doi.org/10.1021/cr500303t open in new tab
  17. Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, Aberg V, Walker JN, Seed PC, Almqvist F, Chapman MR, Hultgren SJ (2009) Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 5: 913- 919. https://doi.org/10.1038/nchembio.242 open in new tab
  18. Chanishvili N (2012) Phage therapy -history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 83: 3-40. https://doi.org/10.1016/B978-0-12-394438-2.00001-3 open in new tab
  19. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, Normark S, Hultgren SJ (2002) Role of Escherichia coli curli op- erons in directing amyloid fiber formation. Science 295: 851-855. https://doi.org/10.1126/science.1067484 open in new tab
  20. Chorell E, Pinkner JS, Phan G, Edvinsson S, Buelens F, Remaut H, Waksman G, Hultgren SJ, Almqvist F (2010) Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyri- dones: pilicides with increased antivirulence activity. J Med Chem 53: 5690-5695. https://doi.org/10.1021/jm100470t open in new tab
  21. Chorell E, Bengtsson C, Sainte-Luce Banchelin T, Das P, Uvell H, Sin- ha AK, Pinkner JS, Hultgren SJ, Almqvist F (2011) Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity. Eur J Med Chem 46: 1103-1116. https://doi.org/10.1016/j.ejmech.2011.01.025 open in new tab
  22. Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson G.H, Gallo RL, Agerberth B, Brauner A (2006) The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 12: 636-641. htt- ps://doi.org/10.1038/nm1407 open in new tab
  23. Collins R, MacMahon S (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 357: 373-380. https://doi.org/10.1016/S0140-6736(00)03651-5 open in new tab
  24. Conover MS, Ruer S, Taganna J, Kalas V, De Greve H, Pinkner JS, Dodson KW, Remaut H, Hultgren SJ (2016) Inflammation-in- duced adhesin-receptor interaction provides a fitness advantage to uropathogenic E. coli during chronic infection. Cell Host Microbe 20: 482-492. https://doi.org/10.1016/j.chom.2016.08.013 open in new tab
  25. Cusumano CK, Pinkner JS, Han Z, Greene SA, Ford BA, Crowley JR, Henderson JP, Janetka JW, Hultgren SJ (2011) Treatment and prevention of urinary tract infection with orally active FimH inhibi- tors. Sci Transl Med 3: 109-115. https://doi.org/10.1126/scitrans- lmed.3003021 open in new tab
  26. Dang HT, Chorell E, Uvell H, Pinkner JS, Hultgren SJ, Almqvist F (2014) Syntheses and biological evaluation of 2-amino-3-acyl-tet- rahydrobenzothiophene derivatives; antibacterial agents with an- tivirulence activity. Org Biomol Chem 12: 1942-1956. https://doi. org/10.1039/c3ob42478b open in new tab
  27. Danilova TM (1996) Phage therapy of the inflammatory urogenital in- fections in women. Proc Dermatol Venerol 5: 75
  28. Das M, Hart-Van Tassell A, Urvil PT, Lea S, Pettigrew D, Anderson KL, Samet A, Kur J, Matthews S, Nowicki S, Popov V, Golusz- ko P, Nowicki BJ (2005) Hydrophilic domain II of Escherichia coli Dr fimbriae facilitates cell invasion. Infect Immun 73: 6119-6126. https://doi.org/10.1128/IAI.73.9.6119-6126.2005 open in new tab
  29. Dhakal BK, Mulvey MA (2012) The UPEC pore-forming toxin α-hemolysin triggers proteolysis of host proteins to disrupt cell ad- hesion, inflammatory, and survival pathways. Cell Host Microbe 11: 58-69. https://doi.org/10.1016/j.chom.2011.12.003 open in new tab
  30. Dodson KW, Pinkner JS, Rose T, Magnusson G, Hultgren SJ, Waks- man G (2001) Structural basis of the interaction of the pyelone- phritic E. coli adhesin to its human kidney receptor. Cell 105: 733- 743 open in new tab
  31. Dueholm MS, Nielsen SB, Hein KL, Nissen P, Chapman M, Chris- tiansen G, Nielsen PH, Otzen DE (2011) Fibrillation of the ma- jor curli subunit CsgA under a wide range of conditions implies a robust design of aggregation. Biochem 50: 8281-8290. https://doi. org/10.1021/bi200967c open in new tab
  32. European Centre for Disease Prevention and Control, European Food Safety Authority and European Medicines Agency (2017) ECDC/ EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobi- al resistance in bacteria from humans and food-producing animals. EFSA J 15: 4872. https://doi.org/10.2903/j.efsa.2017.4872 open in new tab
  33. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Uri- nary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13: 269-284. https://doi. org/10.1038/nrmicro3432 open in new tab
  34. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113: 5S-13S. https://doi. org/ 10.1016/S0002-9343(02)01054-9 open in new tab
  35. Foxman B (2010) The epidemiology of urinary tract infection. Nat Rev Urol 7: 653-660. https://doi.org/ 10.1038/nrurol.2010.190 open in new tab
  36. Foxman B (2014) Urinary tract infection syndromes: occurrence, recur- rence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28: 1-13. https://doi.org/10.1016/j.idc.2013.09.003 open in new tab
  37. Franco AV (2005) Recurrent urinary tract infections. Best Pract Res Clin Obstet Gynaecol 19: 861-873. https://doi.org/10.1016/j.bpob- gyn.2005.08.003 open in new tab
  38. Fronzes R, Remaut H, Waksman G (2008) Architectures and biogen- esis of non-flagellar protein appendages in Gram negative bacteria. EMBO J 27: 2271-2280 https://doi.org/ 10.1038/emboj.2008.155 open in new tab
  39. Garcia EC, Brumbaugh AR, Mobley HL (2011) Redundancy and speci- ficity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun 79: 1225-1235. https://doi.org/10.1128/ IAI.01222-10 open in new tab
  40. Giancola SE, Mahoney MV, Hogan MD, Raux BR, McCoy C, Hirsch EB (2017) Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient charac- teristics and outcomes. Chemotherapy 62: 100-104. https://doi. org/10.1159/000449422 open in new tab
  41. Gordon N (2000) Carbohydrate-deficient glycoprotein syndromes. Post- grad Med J 76: 145-149. https://doi.org/10.1136/pmj.76.893.145 open in new tab
  42. Goyal P, Krasteva PV, Van Gerven N, Gubellini F, Van den Broeck I, Troupiotis-Tsaïlaki A, Jonckheere W, Péhau-Arnaudet G, Pink- ner JS, Chapman MR, Hultgren SJ, Howorka S, Fronzes R, Remaut H (2014) Structural and mechanistic insights into the bacterial am- yloid secretion channel CsgG. Nature 516: 250-253. https://doi. org/10.1038/nature13768 open in new tab
  43. Goluszko P, Goluszko E, Nowicki B, Nowicki S, Popo V, Wang HQ (2005) Vaccination with purified Dr fimbraie reduces mortality asso- ciated with chronic urinary tract infection due to Escherichia coli bear- ing Dr adhesin. Infect Immun 73: 627-631. https://doi.org/10.1128/ IAI.73.1.627-631.2005 open in new tab
  44. Goluszko P, Moseley SL, Truong LD, Kaul A, Williford JR, Selvaran- gan R, Nowicki S, Nowicki B (1997) Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bear- ing Dr fimbriae. J Clin Investig 99: 1662-1672. https://doi.org/ 10.1172/JCI119329 open in new tab
  45. Goluszko P, Niesel D, Nowicki B, Selvarangan R, Nowicki S, Hart A, Pawelczyk E, Das M, Urvil P, Hasan R (2001) Dr operon-associ- ated invasiveness of Escherichia coli from pregnant patients with py- elonephritis. Infect Immun 69: 4678-4680. https://doi.org/ 10.1128/ IAI.69.7.4678-4680 open in new tab
  46. Gorski A, Dabrowska K, Switala-Jeleń K, Nowaczyk M, Weber-Dab- rowska B, Boratynski J, Wietrzyk J, Opolski A (2003a) New insights into the possible role of bacteriophages in host defense and disease. Med Immunol 2: 2. https://doi.org/10.1186/1476-9433-2-2 open in new tab
  47. Gorski A, Nowaczyk M, Weber-Dabrowska B, Kniotek M, Boratynski J, Ahmed A, Dabrowska K, Wierzbicki P, Switala-Jelen K, Opol- ski A (2003b) New insights into the possible role of bacteriophag- es in transplantation. Transplant Proc 35: 2372-2373. https://doi. org/10.1016/S0041-1345(03)00811-X open in new tab
  48. Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Cono- ver MS, Livny J, Hadjifrangiskou M, Almqvist F, Hultgren SJ (2014) Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. mBio 5: e02038. https://doi.org/10.1128/mBio.02038-14 open in new tab
  49. Guglietta A (2017) Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiol 12: 239-246. https://doi.org/10.2217/fmb-2016-0145 open in new tab
  50. Guiton PS, Cusumano, CK, Kline KA, Dodson KW, Han Z, Janetka JW, Henderson JP, Caparon MG, Hultgren SJ (2012) Combinato- rial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob Agents Chemother 56: 4738-4745. https://doi.org/10.1128/AAC.00447-12 open in new tab
  51. Habibi A, Khameneie MK (2016) Antibiotic resistance properties of uropathogenic Escherichia coli isolated from pregnant women with history of recurrent urinary tract infections. Trop J Pharm Res 15: 1745-1750. https://dx.doi.org/10.4314/tjpr.v15i8.21 open in new tab
  52. Hammar M, Bian Z, Normark S (1996) Nucleator-dependent intercel- lular assembly of adhesive curli organelles in Escherichia coli. Proc Natl Acad Sci USA 93: 6562-6566 open in new tab
  53. Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW (2012) Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 55: 3945-3959. https://doi.org/10.1021/jm300165m open in new tab
  54. Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ, Janetka JW (2010) Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53: 4779-4792. https://doi. org/10.1021/jm100438s open in new tab
  55. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE (2010) Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guide- lines from the Infectious Diseases Society of America. Clin Infect Dis 50: 625-663 open in new tab
  56. Hu X, Shi Y, Zhang P, Miao M, Zhang T, Jiang B (2016) d-mannose: properties, production, and applications: an overview. Rev Food Sci Food Saf 15: 773-785. https://doi.org/10.1111/1541-4337.12211 open in new tab
  57. Hung DL, Knight SD, Woods RM, Pinkner JS, Hultgren SJ (1996) Mo- lecular basis of two subfamilies of immunoglobulin-like chaperones. EMBO J 15: 3792-3805. https://doi.org/10.1002/j.1460-2075.1996. tb00753.x open in new tab
  58. Kleeb S, Pang, L, Mayer K, Eris D, Sigl A, Preston RC, Zihlmann P, Sharpe T, Jakob RP, Abgottspon D, Hutter AS, Scharenberg M, Jiang X, Navarra G, Rabbani S, Smiesko M, Lüdin N, Bezençon J, Schwardt O, Maier T, Ernst B (2015) FimH antagonists: bio- isosteres to improve the in vitro and in vivo PK/PD profile. J Med Chem 58: 2221-2239. https://doi.org/10.1021/jm501524q open in new tab
  59. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Luthi C, Scharenberg M, Bezenuon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B. (2010) FimH antag- onists for the oral treatment of urinary tract infections: From de- sign and synthesis to in vitro and in vivo evaluation. J Med Chem 53: 8627-8641. https://doi.org/10.1021/jm101011y open in new tab
  60. Klemm P, Schembri MA (2000) Fimbriae-assisted bacterial surface display of heterologous peptides. Int J Med Microbiol 290: 215-221. https://doi.org/10.1099/00221287-146-12-3025 open in new tab
  61. Kline KA, Dodson KW, Caparon MG, Hultgren SJ (2010) A tale of two pili: assembly and function of pili in bacteria. Trends Microbiol 18: 224-232. https://doi.org/10.1016/j.tim.2010.03.002. open in new tab
  62. Kochiashvili D, Khuskivadze A, Kochiashvili G, Koberidze G, Kvakhajelidze V (2014) Role of the bacterial vaccine Solco-Urovac ® in treatment and prevention of recurrent urinary tract infections of bacterial origin. Georgian Med News 231: 11-16
  63. Kostakioti M, Hultgren SJ, Hadjifrangiskou M (2012) Molecular blue- print of uropathogenic Escherichia coli virulence provides clues to- ward the development of anti-virulence therapeutics. Virulence 3: 592-594. https://doi.org/10.4161/viru.22364 open in new tab
  64. Langermann S, Möllby R, Burlein JE, Palaszynski SR, Auguste CG, De- Fusco A, Strouse R, Schenerman MA, Hultgren SJ, Pinkner SJ, Win- berg J, Guldevall L, Söderhäll M, Ishikawa K, Normark S, Koenig S (2000) Vaccination with FimH adhesin protects cynomolgus mon- keys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 181: 774-778. https://doi.org/10.1086/315258 open in new tab
  65. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ (1997) Prevention of mucosal Escherichia coli infection by FimH-ad- hesin-based systemic vaccination. Science 276: 607-611. https://doi. org/10.1126/science.276.5312.607 open in new tab
  66. Leffler H, Svanborg-Edén C (1981) Glycolipid receptors for uropatho- genic Escherichia coli on human erythrocytes and uroepithelial cells. Infect Immun 34: 920-929 open in new tab
  67. Leitner L, Sybesma W, Chanishvili N, Goderdzishvili M., Chkhotua, A.,Ujmajuridze, A., Schneider MP, Sartori A, Mehnert U, Bachmann LM, Kessler TM (2017). Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the pros- tate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol 17: 90. https://doi.org/10.1186/s12894-017-0283-6 open in new tab
  68. Letkiewicz S, Miedzybrodzki R, Klak M, Jonczyk E, Weber-Dabrowska B, Gorski A (2010) The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol 60: 99-112. https://doi.org/10.1111/j.1574-695X.2010.00723.x Lindhorst TK, Bruegge K, Fuchs A, Sperling O (2010) A bivalent glycopeptide to target two putative carbohydrate binding sites on FimH. Beilstein J Org Chem 6: 801-809. https://doi.org/10.3762/ bjoc.6.90 open in new tab
  69. Loferer H, Hammar M, Normark S (1997) Availability of the fibre subunit CsgA and the nucleator protein CsgB during assembly of fibronectin-binding curli is limited by the intracellular concentration of the novel lipoprotein CsgG. Mol Microbiol 26: 11-23 open in new tab
  70. MacMahon S, Collins R (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observation- al studies. Lancet 357: 455-62. https://doi.org/10.1016/S0140- 6736(00)04017-4 open in new tab
  71. Maddirala A, Klein RD, Pinkner J, Kalas V, Hultgren SJ, Janetka JW (2018) Biphenyl Gal and GalNAc FmlH Lectin Antago- nists of Uropathogenic E. coli (UPEC): Optimization through it- erative rational drug design. J Med Chem 62: 467-479. https://doi. org/10.1021/acs.jmedchem.8b01561 open in new tab
  72. Mike LA, Smith SN, Sumner CA, Eaton KA, Mobley HL (2016) Sid- erophore vaccine conjugates protect against uropathogenic Escherich- ia coli urinary tract infection. Proc Natl Acad Sci U S A 113: 13468- 13473. https://doi.org/10.1073/pnas.1606324113 open in new tab
  73. Mousavifar L, Touaibia M, Roy R (2018) Development of mannopy- ranoside therapeutics against adherent-invasive Escherichia coli infec- tions. Acc Chem Res 51: 2937-2948. https://doi.org/10.1021/acs. accounts.8b00397 open in new tab
  74. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ (2009) Immunoac- tive prophylaxis of recurrent urinary tract infections: a meta-analysis. open in new tab
  75. Int J Antimicrob Agents 33: 111-119. https://doi.org/10.1016/j.ijanti- micag.2008.08.011 open in new tab
  76. Nenninger AA, Robinson LS, Hultgren SJ (2009) Localized and effi- cient curli nucleation requires the chaperone-like amyloid assembly protein CsgF. Proc Natl Acad Sci USA 106: 900-905. https://doi. org/10.1073/pnas.0812143106 open in new tab
  77. Neto TKA, Nogueira CL, Reis LO (2016) Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic re- view with meta-analysis. Actas Urol Esp 40: 203-208. https://doi. org/10.1016/j.acuro.2015.04.008 open in new tab
  78. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM (2005) Infectious diseases society of America guidelines for the di- agnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 40: 643-654. https://doi.org/10.1086/427507 open in new tab
  79. Nielsen KL, Dynesen P, Larsen P, Jakobsen L, Andersen PS, Fri- modt-Møller N (2014) Role of urinary cathelicidin LL-37 and hu- man β-defensin 1 in uncomplicated Escherichia coli urinary tract infections. Infect Immun 82: 1572-1578. https://doi.org/10.1128/ IAI.01393-13 open in new tab
  80. Nowicki B, Martens M, Hart A, Nowicki S (1994) Gestational age-de- pendent distribution of Escherichia coli fimbriae in pregnant patients with pyelonephritis. Ann N Y Acad Sci 730: 290-291. https://doi. org/10.1111/j.1749-6632.1994.tb44268.x open in new tab
  81. Nowicki B, Rhen M, Väisänen-Rhen V, Pere A, Korhonen TK (1984) Immunofluorescence study of fimbrial phase variation in Esch- erichia coli KS71. J Bacteriol 160: 691-695. https://doi.org/0021- 9193/84/110691-05$02.00/0 open in new tab
  82. O'Brien VP, Dorsey DA, Hannan TJ, Hultgren SJ (2018) Host restric- tion of Escherichia coli recurrent urinary tract infection occurs in a bacterial strain-specific manner. PLoS Pathog 14: e1007457. https:// doi.org/10.1371/journal.ppat.1007457 open in new tab
  83. O'Hanley P, Lalonde G, Ji G (1991) Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect Immun 59: 1153-1161 open in new tab
  84. Perepanova TS, Darbeeva OS, Kotliarova GA, Kondrat'eva EM, Maĭskaia LM, Malysheva VF, Baĭguzina FA, Grishkova N (1995) The efficacy of bacteriophages preparations in treatment of inflam- matory urogenital diseases. Urol Nephrol 5: 14-17
  85. Piątek R, Zalewska-Piątek B, Dzierzbicka K, Makowiec S, Pilipczuk J, Szemiako K, Cyranka-Czaja A, Wojciechowski M (2013) Pilicides inhibit the FGL chaperone/usher assisted biogenesis of the fimbri- al polyadhesin from uropathogenic Escherichia coli. BMC Microbiol 13: 131. https://doi.org/10.1186/1471-2180-13-131 open in new tab
  86. Pinkner JS, Remaut H, Buelens F, Miller E, Aberg V, Pemberton N, Hedenström M, Larsson A, Seed P, Waksman G, Hultgren SJ, Almqvist F (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA 103: 17897-17902. https://doi.org/10.1073/pnas.0606795103 open in new tab
  87. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De Vos D, Gab- ard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Va- neechoutte M, Van Parys L, Verbeken G, Zizi M, Van den Eede G (2015) Quality and safety requirements for sustainable phage ther- apy products. PharmRes 32: 2173-2179. https://doi.org/10.1007/ s11095-014-1617-7 open in new tab
  88. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Va- neechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Moot- er G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R (2011) The phage therapy para- digm: pret-a-porter or sur-mesure? PharmRes 28: 934-937. https:// doi.org/10.1007/s11095-010-0313-5 open in new tab
  89. Remaut H, Rose RJ, Hannan TJ, Hultgren SJ, Radford SE, Ashcroft AE, Waksman G (2006) Donor-strand exchange in chaperone- assisted pilus assembly proceeds through a concerted beta strand displacement mechanism. Mol Cell 22: 831-842. https://doi. org/10.1016/j.molcel.2006.05.033 open in new tab
  90. Remaut H, Tang C, Henderson N, Pinkner J,Wang T, Hultgren S, Thanassi D,Waksman G, Li H (2008) Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell 133: 640-652. https://doi.org/10.1016/j.cell.2008.03.033 open in new tab
  91. Roberts JA, Hardaway K, Kaack B, Fussell EN, Baskin G (1984) Pre- vention of pyelonephritis by immunization with P-fimbriae. J Urol 131: 602-607. https://doi.org/10.1016/S0022-5347(17)50513-3 open in new tab
  92. Roberts JA, Kaack MB, Baskin G, Chapman MR, Hunstad DA, Pinkner JS, Hultgren SJ (2004) Antibody responses and protec- tion from pyelonephritis following vaccination with purified Es- cherichia coli PapDG protein. J Urol 171: 1682-1685. https://doi. org/10.1097/01.ju.0000116123.05160.43 open in new tab
  93. Roberts JA, Marklund BI, Ilver D, Haslam D, Kaack MB, Baskin G, Louis M, Möllby R, Winberg J, Normark S (1994) The Gal(alpha 1-4)Gal-specific tip adhesin of Escherichia coli P-fimbriae is need- ed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci USA 91: 11889-11893. https://doi.org/10.1073/ pnas.91.25.11889 open in new tab
  94. Robinson LS, Ashman EM, Hultgren SJ, Chapman MR (2006) Secre- tion of curli fibre subunits is mediated by the outer membrane- localized CsgG protein. Mol Microbiol 59: 870-881. https://doi. org/10.1111/j.1365-2958.2005.04997.x open in new tab
  95. Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE (2003) The Siderophore receptor IroN of extraintes- tinal pathogenic Escherichia coli is a potential vaccine candidate. In- fect Immun 71: 7164-7169. https://doi.org/10.1128/IAI.71.12.7164- 7169.2003 open in new tab
  96. Sauer MM, Jakob RP, Eras J, Baday S, Eriş D, Navarra G, Bernèche S, Ernst B, Maier T, Glockshuber R (2016) Catch-bond mechanism of the bacterial adhesin FimH. Nat Commun 7: 10738. https://doi. org/10.1038/ncomms10738 open in new tab
  97. Savar NS, Jahanian-Najafabadi A, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S (2014) In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. J Biotechnol 175: 31-37. https://doi. org/10.1016/j.jbiotec.2014.01.037 open in new tab
  98. Sivick KE, Mobley HL (2010) Waging war against uropathogenic Es- cherichia coli: winning back the urinary tract. Infect Immun 78: 568-585. https://doi.org/10.1128/IAI.01000-09 open in new tab
  99. Sokurenko EV, Chesnokova V, Doyle RJ, Hasty DL (1997) Diversity of the Escherichia coli type 1 fimbrial lectin. Differential binding to mannosides and uroepithelial cells. J Biol Chem 272: 17880-17886 open in new tab
  100. Soto GE, Hultgren SJ (1999) Bacterial adhesins: common themes and variations in architecture and assembly. J Bacteriol 181: 1059-1071. https://doi.org/10.1111/j.1574-6976.2007.00075.x open in new tab
  101. Spaulding CN, Hultgren SJ (2016) Adhesive pili in UTI pathogenesis and drug development Pathogen 5: E30. https://doi.org/10.3390/ pathogens5010030 open in new tab
  102. Spaulding CN, Schreiber HL 4th, Zheng W, Dodson KW, Hazen JE, Conover MS, Wang F, Svenmarker P, Luna-Rico A, Francetic O, Andersson M, Hultgren S, Egelman EH (2018) Functional role of the type 1 pilus rod structure in mediating host-pathogen interac- tions. eLife 7 pii: e31662. https://doi.org/10.7554/eLife.31662 open in new tab
  103. Stamm WE, Norrby SR (2001) Urinary tract infections: disease panorama and challenges. J Infect Dis 183: S1-S4. https://doi. org/10.1086/318850 open in new tab
  104. Stork C, Kovács B, Rózsai B, Putze J, Kiel M, Dorn Á, Kovács J, Melegh S, Leimbach A, Kovács T, Schneider G, Kerényi M, Emödy L, Dobrindt U (2018) Characterization of asymptomatic bacteriuria Escherichia coli isolates in search of alternative strains for efficient bacterial interference against uropathogens. Front Microbiol 9: 214. https://doi.org/10.3389/fmicb.2018.00214 open in new tab
  105. Svennson A, Larsson A, Erntenäs H, Hedenström M, Fex T, Hulgren S, Pinker J, Almqvist F, Kihlberg J (2001) Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2: 915-918 open in new tab
  106. Sybesma W, Zbinden R, Chanishvili N, Kutateladze M, Chkhotua A, Ujmajuridze A, Mehnert U, Kessler TM (2016) Bacteriophages as potential treatment for urinary tract infections. Front Microbiol 7: 465. https://doi.org/10.3389/fmicb.2016.00465 open in new tab
  107. Terlizzi ME, Gribaudo G, Maffei ME (2017) UroPathogenic Escherichia coli (UPEC) Infections: virulence factors, bladder responses, anti- biotic, and non-antibiotic antimicrobial strategies. Front Microbiol 8: 1566. https://doi.org/10.3389/fmicb.2017.01566 open in new tab
  108. Thanassi DG, Saulino ET, Hultgren SJ (1998) The chaperone/usher pathway: a major terminal branch of the general secretory pathway. Curr Opin Microbiol 1: 223-231. https://doi.org/10.1016/S1369- 5274(98)80015-5 open in new tab
  109. Tomašić T, Rabbani S, Gobec M, Raščan IM, Podlipnik Č, Ernst B, Anderluh M (2014) Branched α-D-mannopyranosides: a new class of potent FimH antagonists. Med Chem Commun 5: 1247-1253. htt- ps://doi.org/10.1039/C4MD00165F open in new tab
  110. Totsika M, Kostakioti M, Hannan TJ, Upton M, Beatson SA, Janetka JW, Hultgren SJ, Schembri MA (2013) A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multi- drug-resistant uropathogenic Escherichia coli ST131. J Infect Dis 208: 921-928. https://doi.org/10.1093/infdis/jit245 open in new tab
  111. Touaibia M, Roy R (2007) Glycodendrimers as anti-adhesion drugs against type 1 fimbriated E. coli uropathogenic infections. Mini-Rev Med Chem 7: 1270-1283 open in new tab
  112. Ujmajuridze A, Chanishvili N, Goderdzishvili M, Leitner L, Mehnert U, Chkhotua A, Kessler TM, Sybesma W (2018) Adapted bacterio- phages for treating urinary tract infections. Front Microbiol 9: 1832. https://doi.org/10.3389/fmicb.2018.01832 open in new tab
  113. Valore EV, Park CH, Quayle AJ, Wiles KR, McCray PB Jr, Ganz T (1998) Human beta-defensin-1: an antimicrobial peptide of urogen- ital tissues. J Clin Invest 101: 1633-1642. https://doi.org/10.1172/ JCI1861 open in new tab
  114. Vandenbroucke JP (2004) When are observational studies as credible as randomised trials? Lancet 363: 1728-1731. https://doi.org/10.1016/ S0140-6736(04)16261-2 open in new tab
  115. Waksman G, Hultgren SJ (2009) Structural biology of the chaper- one-usher pathway of pilus biogenesis. Nat Rev Microbiol 7: 765-774. https://doi.org/10.1038/nrmicro2220 open in new tab
  116. Wang X, Smith DR, Jones JW, Chapman MR (2007) In vitro polym- erization of a functional Escherichia coli amyloid protein. J Biol Chem 282: 3713-3719. https://doi.org/10.1074/jbc.M609228200 open in new tab
  117. Weber-Dabrowska B, Dabrowski M, Slopek S (1987) Studies on bac- teriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 35: 563-568
  118. Weber-Dabrowska B, Mulczyk M, Górski A (2003) Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Trans- plant Proc 35: 1385-1386 open in new tab
  119. Werneburg GT, Thanassi DG (2018) Pili assembled by the chaperone/ usher pathway in Escherichia coli and Salmonella. EcoSal Plus 8: 1-37. https://doi.org/10.1128/ecosalplus open in new tab
  120. Wolski Z (2017) The application of Uro-Vaxom in the prevention and treatment of urinary tract infections caused by bacteria other than colon Escherichia coli. Przegl Urol 3: 1-26 (in Polish)
  121. Wurpel DJ, Beatson SA, Totsika M, Petty NK, Schembri MA (2013) Chaperone-usher fimbriae of Escherichia coli. PLoS One 8: e52835. https://doi.org/10.1371/journal.pone.0052835 open in new tab
  122. Zalewska B, Piatek R, Konopa G, Nowicki B, Nowicki S, Kur J (2003) Chimeric Dr fimbriae with a herpes simplex virus type 1 epitope as a model for a recombinant vaccine. Infect Immun 71: 5505-5513. https://doi.org/10.1128/IAI.71.10.5505-5513.2003 open in new tab
  123. Zalewska B, Stangret J, Bury K, Wojciechowski M, Kur J, Piatek R (2007) DAF-and collagen-binding properties of chimeric Dr fimbriae. Microbiol 153: 2733-2742. https://doi.org/10.1099/ mic.0.2006/003525-0 open in new tab
  124. Zavialov A, Zav'yalova G, Korpela T, Zav'yalov V (2007) FGL chap- erone-assembled fimbrial polyadhesins: anti-immune armament of Gram-negative bacterial pathogens. FEMS Microbiol. Rev 31: 478- 514. https://doi.org/10.1111/j.1574-6976.2007.00075.x open in new tab
  125. Zav'yalov V, Zavialov A, Zav'yalova G, Korpela T (2010) Adhesive organelles of Gram-negative pathogens assembled with the clas- sical chaperone/usher machinery: structure and function from a clinical standpoint. FEMS Microbiol Rev 34: 317-378. https://doi. org/10.1111/j.1574-6976 open in new tab
  126. Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, Williamson DA, Paterson DL (2015) The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 12: 570-584. https://doi.org/10.1038/nrurol.2015.199 open in new tab
Verified by:
Gdańsk University of Technology

seen 108 times

Recommended for you

Meta Tags